View:
================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) July 30, 2004
HAEMONETICS CORPORATION
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Massachusetts 1-10730 04-2882273
- ---------------------------- ---------------- -------------
(State or other jurisdiction (Commission File (IRS Employer
of incorporation) Number) Identification No.)
400 Wood Road Braintree, MA 02184
- ---------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (781) 848-7100
- --------------------------------------------------------------------------------
(Former name or former address if changed since last report)
================================================================================
Item. 5 OTHER EVENTS AND REGULATION FD DISCLOSURE
On July 30, 2004, Haemonetics Corporation, (the "Company") announced the
reelection of Dr. Yutaka Sakurada to the Company's Board of Directors. Dr.
Harvey Klein withdrew his name from the slate of candidates to be elected
to the Board in response to a recently announced policy by National
Institutes of Health ("NIH") against having NIH employees serve on
for-profit boards. Dr. Klein serves as the Chief of the Department of
Transfusion medicine at the Warren G. Magnuson Clinical Center of NIH.
Item. 7 FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits
99.1: Press Release of Haemonetics Corporation dated July 30, 2004
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
(Registrant)
Date: July 30, 2004 By: /s/ Ronald J. Ryan
----------------------------------
Ronald J. Ryan, Vice President and
Chief Financial Officer
2
EXHIBIT INDEX
Exhibit No. Subject Matter
99.1 Press Release of Haemonetics Corporation dated July 30, 2004.
3
Exhibit 99.1
Haemonetics Announces Change in Board of Directors
BRAINTREE, Mass., July 30 /PRNewswire-FirstCall/ -- Haemonetics
Corporation announced today the reelection of Dr. Yutaka Sakurada to the
Company's Board of Directors as part of the director class of 2005, at its
annual shareholders meeting. Dr. Harvey Klein withdrew his name from the
slate of candidates to be elected to the Board in response to a recently
announced policy by National Institutes of Health ("NIH") against having NIH
employees serve on for-profit boards. Dr. Klein is Chief of the Department of
Transfusion Medicine at the Warren G. Magnuson Clinical Center of NIH, and has
served with distinction on Haemonetics' Board of Directors since 1998.
Haemonetics expects to accelerate its consideration of independent
director candidates to its Board.
Haemonetics Corporation
Haemonetics (NYSE: HAE) is a global company engaged in the design,
manufacture and worldwide marketing of automated blood processing systems.
These systems address important medical markets: surgical blood salvage, blood
component collection, plasma collection, and blood component safety. To learn
more about Haemonetics' products and markets, visit its web site at
http://www.haemonetics.com.
This release contains forward looking statements that involve risks and
uncertainties, including technological advances in the medical field and
standards for transfusion medicine and our ability to successfully implement
products that incorporate such advances and standards, product demand, market
acceptance, regulatory uncertainties, the effect of economic and political
conditions, the impact of competitive products and pricing, blood product
reimbursement policies and practices, foreign currency exchange rates, changes
in customers' ordering patterns, the effect of industry consolidation as seen
in the plasma market, the effect of communicable diseases and the effect of
uncertainties in markets outside the U.S. (including Europe and Asia) in which
we operate and other risks detailed in the Company's filings with the
Securities and Exchange Commission. The foregoing list should not be
construed as exhaustive. The forward-looking statements are based on
estimates and assumptions made by management of the Company and are believed
to be reasonable, though are inherently uncertain and difficult to predict.
Actual results and experience could differ materially from the forward-looking
statements.
Contact:
Julie Fallon
Tel. (781) 356-9517
Alt. Tel. (617) 320-2401
fallon@haemonetics.com
SOURCE Haemonetics Corporation
-0- 07/30/2004
/CONTACT: Julie Fallon of Haemonetics Corporation, +1-781-356-9517, Alt.
Tel. +1-617-320-2401, fallon@haemonetics.com/
/Web site: http://www.haemonetics.com/
(HAE)
CO: Haemonetics Corporation
ST: Massachusetts
IN: HEA MTC
SU: PER